Exchange Traded Concepts, LLC Mirati Therapeutics, Inc. Transaction History

Exchange Traded Concepts, LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Jan 05, 2024	BUY	$41.99 - $62.38 $45,181 - $67,120	1,076 Added 33.99%	4,242 $249,000
Q3 2023 Oct 18, 2023	SELL	$27.8 - $45.35 $15,873 - $25,894	-571 Reduced 15.28%	3,166 $137,000
Q2 2023 Jul 20, 2023	BUY	$36.13 - $49.49 $135,017 - $184,944	3,737 New	3,737 $135,000
Q1 2022 Apr 26, 2022	SELL	$75.82 - $150.97 $229,052 - $456,080	-3,021 Closed	0 $0
Q4 2021 Jan 13, 2022	BUY	$132.01 - $190.29 $398,802 - $574,866	3,021 New	3,021 $443,000

Q2 2021 Jul 30, 2021	SELL	$144.0 - $179.73 $120,672 - $150,613	-838 Closed	0 $0
Q1 2021 Apr 20, 2021	BUY	$158.92 - $221.61 $73,738 - $102,827	464 Added 124.06%	838 $144,000
Q4 2020 Jan 19, 2021	BUY	$162.05 - $240.27 $60,606 - $89,860	374 New	374 $82,000

3.57M

36.6K

Ticker MRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,609,800
Description
Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; ...

Get notified when there are updates to the investment portfolio of Exchange Traded Concepts, LLC, based on Form 13F filings with the SEC.

Stay updated on Exchange Traded Concepts, LLC with notifications on news.